Sign Out
Agranulocytosis and thrombocytopenia: Since agranulocytosis or thrombocytopenia may occur, patients should be carefully monitored. If any abnormality is observed, appropriate therapeutic measures such as discontinuing administration should be taken.
Ventricular extrasystole and supraventricular extrasystole: Since ventricular extrasystole and supraventricular extrasystole may occur, patients should be carefully monitored. If such symptoms are observed, administration should be discontinued and appropriate therapeutic measures taken.
Erythroderma: Since erythroderma may occur, patients should be carefully monitored. If such symptoms are observed, administration should be discontinued and appropriate therapeutic measures taken.
Other Adverse Reactions: See Table 6.
Click on icon to see table/diagram/image
View ADR Reporting Link
Continue with Google